

# Mauritania

Population 2015

4.1 million

| Estimates of TB burden*, 2015 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.84 (0.5–1.3)     | 21 (12–31)                    |
| Mortality (HIV+TB only)       | 0.14 (0.054–0.27)  | 3.5 (1.3–6.7)                 |
| Incidence (includes HIV+TB)   | 4.3 (2.8–6.2)      | 107 (69–152)                  |
| Incidence (HIV+TB only)       | 0.44 (0.27–0.66)   | 11 (6.6–16)                   |
| Incidence (MDR/RR-TB)**       | 0.15 (0–0.32)      | 3.7 (0–7.9)                   |

## Estimated TB incidence by age and sex (thousands)\*, 2015

|         | 0-14 years       | > 14 years     | Total          |
|---------|------------------|----------------|----------------|
| Females | 0.23 (0.064–0.4) | 1.2 (0.32–2.1) | 1.4 (0.38–2.5) |
| Males   | 0.31 (0.18–0.45) | 2.6 (1.8–3.4)  | 2.9 (1.9–3.9)  |
| Total   | 0.55 (0.34–0.75) | 3.8 (2.8–4.7)  | 4.3 (2.8–6.2)  |

## TB case notifications, 2015

|  |       |
|--|-------|
| Total cases notified                                   | 2 193 |
| Total new and relapse                                  | 2 166 |
| - % tested with rapid diagnostics at time of diagnosis |       |
| - % with known HIV status                              |       |
| - % pulmonary  | 75%   |
| - % bacteriologically confirmed among pulmonary        | 81%   |

## Universal health coverage and social protection

|  |                 |
|--|-----------------|
| TB treatment coverage (notified/estimated incidence), 2015             | 50% (35–77)     |
| TB patients facing catastrophic total costs                            |                 |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.24 (0.13–0.4) |

## TB/HIV care in new and relapse TB patients, 2015

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive |        |     |
| - on antiretroviral therapy                         |        |     |

| Drug-resistant TB care, 2015                                | New cases      | Previously treated cases | Total number*** |
|---|----------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                |                          | 69 (5–130)      |
| Estimated % of TB cases with MDR/RR-TB                      | 2.8% (0.1–6.7) | 21% (2.2–39)             |                 |
| % notified tested for rifampicin resistance                 | 13%            | 26%                      | 297             |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                |                          | 0               |
| Laboratory-confirmed cases                                  |                | MDR/RR-TB: 24, XDR-TB: 0 |                 |
| Patients started on treatment ****                          |                | MDR/RR-TB: 13, XDR-TB: 0 |                 |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2014                        | 70%     | 2 420  |
| Previously treated cases, excluding relapse, registered in 2014 | 62%     | 13     |
| HIV-positive TB cases, all types, registered in 2014            |         | 0      |
| MDR/RR-TB cases started on second-line treatment in 2013        | 43%     | 7      |
| XDR-TB cases started on second-line treatment in 2013           |         | 0      |

## TB preventive treatment, 2015

|   |    |
|---|----|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   | 0% |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |    |

## TB financing, 2016

|                                    |  |
|------------------------------------|--|
| National TB budget (US\$ millions) |  |
|------------------------------------|--|

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015




## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically